Clinical outcomes of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma

Table 1 General characteristics of all patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma included in this study

	Total, n = 155	Duodenum, n = 99	Papilla, n = 56	P value
Age				0.237
Age, median [IQR]	64 [58-73]	63 [56-72]	66 [58-74]
Sex (%)				0.742
Male	94 (60.6)	61 (61.6)	33 (58.9)
ASA (%)				0.852
ASA I	19 (12.3)	12 (12.1)	7 (12.5)
ASA II	83 (53.5)	49 (49.5)	34 (60.7)
ASA III	31 (20.0)	19 (19.2)	12 (21.4)
ASA IV	1 (0.6)	1 (1.0)	0 (0.0)
NR	21 (13.5)	18 (18.2)	3 (5.4)
TNM stage (%)				< 0.001
Stage I	25 (16.1)	7 (7.1)	18 (32.1)
Stage II	26 (16.8)	20 (20.2)	6 (10.7)
Stage III	65 (41.9)	39 (39.4)	26 (46.4)
Stage IV	34 (21.9)	29 (29.3)	5 (8.9)
NR	5 (3.2)	4 (4.0)	1 (1.8)
Treatment (%)
Curative intent	122 (78.7)	71 (71.7)	51 (91.1)	0.003
Surgery	89 (73.0)	43 (60.6)	46 (90.2)
Neoadjuvant + surgery	3 (2.5)	3 (4.2)	0 (0.0)
Surgery + adjuvant therapy	21 (17.2)	17 (23.9)	4 (7.8)
Primary resection + treatment metastasis	9 (7.4)	8 (11.3)	1 (2.0)
Palliative treatment	23 (14.8)	20 (20.2)	3 (5.4)	0.848
Chemotherapy	21 (91.3)	18 (90.0)	3 (100.0)
Radiotherapy	1 (4.3)	1 (5.0)	0 (0.0)
Chemotherapy + radiotherapy	1 (4.3)	1 (5.0)	0 (0.0)
Best-supportive care	8 (5.2)	7 (7.1)	1 (1.8)
NR	2 (1.3)	1 (1.0)	1 (1.8)

Duodenum: Duodenal adenocarcinoma; Papilla: Intestinal-type papilla of Vater Adenocarcinoma; ASA: American Society of Anesthesiologists physical status classification system (ASA-score); TNM: disease stage according to the American Joint Committee on Cancer staging system (AJCC 7^th edition); IQR: Interquartile range; NR: Not reported.

Table 2 General characteristics of all patients with stage IV duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma, n (%)

	Total, n = 31	Local treatment of metastases, n = 7	Systemic treatment, n = 20	Supportive care, n = 4
Age
Age, median [IQR]	63 [58-71]	69 [59-73]	62 [52-73]	63 [58-67]
Sex
Male	17	5	11	1
Origin
Duodenum	27	7	17	3
Papilla (intestinal-type)	4	0	3	1
ASA
ASA I	3	1	2	0
ASA II	13	4	8	1
ASA III	4	1	1	2
NR	11	1	9	1
Metastatic site
Liver	13	5	7	1
Lymphatic	4	2	2	0
Lung	2	0	2	0
Peritoneal	9	0	6	3
Lung + liver or lymphatic	3	0	3	0
Number of liver oligometastases1 (%)
Number, median [IQR]	2 [1-7]	2 [1-3]	4 [1-15]	3
Local treatment of liver metastases
Metastasectomy	5 (14.7)	5	N/A	N/A
Ablation	1 (2.9)	1	N/A	N/A
Metastasectomy + ablation	1 (2.9)	1	N/A	N/A
Systemic therapy
5-FU-LV	1 (2.9)	0	1	0
Capecitabine	5 (14.7)	0	5	0
CAPOX	13 (41.9)	2	11	0
EOX	1 (2.9)	0	1	0
FOLFOX	1 (2.9)	1	0	0
FOLFOX + radiotherapy	1 (2.9)	0	1	0
No chemotherapy	6 (19.4)	3	0	3
Unspecified chemotherapy	1 (2.9)	0	1	0
NR	2 (6.5)	1	0	1

¹Only patients with oligometastases of the liver. 5-FU-LV: 5-fluorouracil and leucovorin; CAPOX: Capecitabine and oxaliplatin; EOX: Epirubicine, oxaliplatin and capecitabine; FOLFOX: 5-fluorouracil and oxaliplatin; IQR: Interquartile range; NR: Not reported; N/A: Not applicable.